<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vtio</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник трансплантологии и искусственных органов</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Transplantology and Artificial Organs</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-1191</issn><publisher><publisher-name>Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15825/1995-1191-2019-1-122-134</article-id><article-id custom-type="elpub" pub-id-type="custom">vtio-998</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Регенеративная медицина и клеточные технологии</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Regenerative Medicine and Cell Technologies</subject></subj-group></article-categories><title-group><article-title>Влияние соотношения клеток печени и ММСК костного мозга в имплантируемых клеточно-инженерных конструкциях печени на эффективность восстановления функциональных и морфологических показателей при хронической печеночной недостаточности</article-title><trans-title-group xml:lang="en"><trans-title>The influence of the ratio of liver cells and bone marrow in the implantable cell-engineering structures of the liver on the recovery efficiency of functional and morphological parameters in chronic liver failure</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шагидулин</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Shagidulin</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>123182, Москва, ул. Щукинская, д. 1.Тел. (499) 196-87-90. </p></bio><bio xml:lang="en"><p>1, Shchukinskaya str., Moscow, 123182.Теl. (499) 196-87-90.</p></bio><email xlink:type="simple">dr.shagidulin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Онищенко</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Onishchenko</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крашенинников</surname><given-names>М. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Krasheninnikov</surname><given-names>M. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никольская</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikolskaya</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волкова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ильинский</surname><given-names>И. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Iljinsky</surname><given-names>I. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Можейко</surname><given-names>Н. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Mogeiko</surname><given-names>N. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Севастьянов</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Sevastianov</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Готье</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gautier</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>17</day><month>05</month><year>2019</year></pub-date><volume>21</volume><issue>1</issue><fpage>122</fpage><lpage>134</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шагидулин М.Ю., Онищенко Н.А., Крашенинников М.Е., Никольская А.О., Волкова Е.А., Ильинский И.М., Можейко Н.П., Севастьянов В.И., Готье С.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Шагидулин М.Ю., Онищенко Н.А., Крашенинников М.Е., Никольская А.О., Волкова Е.А., Ильинский И.М., Можейко Н.П., Севастьянов В.И., Готье С.В.</copyright-holder><copyright-holder xml:lang="en">Shagidulin M.Y., Onishchenko N.A., Krasheninnikov M.E., Nikolskaya A.O., Volkova E.A., Iljinsky I.M., Mogeiko N.P., Sevastianov V.I., Gautier S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.transpl.ru/vtio/article/view/998">https://journal.transpl.ru/vtio/article/view/998</self-uri><abstract><sec><title>Цель работы</title><p>Цель работы: выявить наиболее эффективное соотношение клеток печени и мультипотентных мезенхимальных стромальных клеток костного мозга (ММСК КМ) в имплантируемых клеточно-инженерных конструкциях (КИК), используемых для коррекции хронической печеночной недостаточности (ХПН).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы.Для создания КИК печени использовался биополимерный имплантат – композиция гетерогенного коллагенсодержащего геля (БМКГ) (торговый знак Сферо®ГЕЛЬ), содержащая жизнеспособные клетки печени и ММСК КМ в следующих соотношениях – 1 : 1; 5 : 1 и 10 : 1 соответственно. КИК с различным соотношением клеток печени и ММСК КМ имплантировали в печень крыс с хронической печеночной недостаточностью (ХПН), которую моделировали путем затравки крыс CCL4. Эффективность регуляторного воздействия КИК (с различным соотношением клеток) на восстановительные процессы в печени оценивали с помощью биохимических, морфологических и морфометрических методов на разных сроках после имплантации.</p></sec><sec><title>Результаты</title><p>Результаты. Установлено корригирующее воздействие КИК различного клеточного состава на биохимические и морфологические показатели печени при ХПН. При изучении КИК печени различного клеточного соотношения клеток печени и ММСК КМ (1 : 1; 5 : 1 и 10 : 1 соответственно) установлено, что наиболее оптимальным соотношением клеток в составе КИК является 5 : 1, т. к. при таком соотношении клеток имела место более отчетливая нормализация морфофункциональных показателей ткани печени при ХПН в течение 365 суток наблюдения при сохранении структурного гомеостаза самих КИК.</p></sec><sec><title>Заключение</title><p>Заключение. Эффективная коррекция хронической печеночной недостаточности может быть осуществлена с помощью имплантируемых КИК печени, в которых донорские клетки печени и ММСК КМ находятся в соотношении 1 : 1; 5 : 1 и 10 : 1. Анализ результатов пролонгированной коррекции структурных и функциональных показателей печени с помощью КИК позволяет рекомендовать предпочтительное использование КИК с соотношением клеток печени и ММСК КМ 5 : 1, т. к. длительное сохранение структурного гомеостаза в самих КИК позволяет прогнозировать их длительное регуляторное воздействие на ткань печени при ХПН, в том числе у реципиентов, находящихся в листе ожидания на трансплантацию печени.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim: to determinate the most effective liver cells and multipotent mesenchymal stromal cells of bone marrow (MMSC BM) ratio into implantable cell engineering constructions (CECs) used for chronic liver failure (CLF) correcting.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. For creating liver CECs it was used a biopolymer implant – a composition of a heterogeneous collagen-containing gel (BMCG) (Sphero®GEL trademark) containing viable liver cells and MMSC BM in the following ratios – 1 : 1; 5 : 1 and 10 : 1 respectively. CECs with different ratios of liver cells and MMSC BM were implanted into liver of rats in which chronic liver failure (CLF), was modeled by using CCl4. The effectiveness of the regulatory effects of CECs (with different cell ratios) on regenerative processes in livers were assessed by using biochemical, morphological and morphometric methods at different periods after their implantation.</p></sec><sec><title>Results</title><p>Results. Corrective effect of CECs with different cell composition on biochemical and morphological parameters of livers at chronic liver failure was established. During studying the liver CECs with various cell ratios of liver cells and MMSC BM (1 : 1; 5 : 1 and 10 : 1 respectively), it was found that the most optimal ratio of cells into the CECs is 5 : 1, because at this ratio of cells, there were a more distinct normalization of the morphological and functional liver parameters within 365 days after modeling CLF and maintenance of the structural homeostasis into the CECs. Themselves, which allows predicting their long-term regulatory effect on the liver tissue in CLF and maintaining its normal structural and functional state.</p></sec><sec><title>Conclusion</title><p>Conclusion. The effective correction of chronic liver failure can be carried out by using the implanted liver CECs, in which donor liver cells and MMSC BM where presented in ratios – 1 : 1; 5 : 1 and 10 : 1. But analysis of prolonged correction of liver morphological and functional parameters at CECs using it was allow to recommend the preferences using of CECs with ratio 5 : 1, because prolonged preservation of structural homeostasis into these CECs makes possible to prognosticate their prolonged regulatory action on the liver tissue at CLF, especially for recipients on a waiting list for liver transplantation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>печень</kwd><kwd>печеночная недостаточность</kwd><kwd>регенерация</kwd><kwd>трансплантация клеток</kwd><kwd>клеточно-инженерные конструкции</kwd><kwd>биоискусственные органы</kwd><kwd>биодеградируемые матриксы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>liver</kwd><kwd>liver failure</kwd><kwd>regeneration</kwd><kwd>cell transplantation</kwd><kwd>cell-engineering construction</kwd><kwd>bioartificial organs</kwd><kwd>biodegradable matrices</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">WHO. World health statistics 2016: monitoring health for the SDGs, sustainable development goals. World Health Organization, Geneva; 2016.</mixed-citation><mixed-citation xml:lang="en">WHO. World health statistics 2016: monitoring health for the SDGs, sustainable development goals. World Health Organization, Geneva; 2016.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385: 117–171.</mixed-citation><mixed-citation xml:lang="en">GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385: 117–171.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Forbes S, Strom S. Stem Cells and Hepatocyte Transplantation. A Textbook of Liver Disease. 2018: 84–97.e3. https://doi.org/10.1016/B978-0-323-37591-7.00006-9.</mixed-citation><mixed-citation xml:lang="en">Forbes S, Strom S. Stem Cells and Hepatocyte Transplantation. A Textbook of Liver Disease. 2018: 84–97.e3. https://doi.org/10.1016/B978-0-323-37591-7.00006-9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: From liver transplantation to cell factory. J Hepatol. 2015; 62 (1 Suppl): 157–169. doi: 10.1016/j.jhep.2015.02.040.</mixed-citation><mixed-citation xml:lang="en">Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: From liver transplantation to cell factory. J Hepatol. 2015; 62 (1 Suppl): 157–169. doi: 10.1016/j.jhep.2015.02.040.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Готье СВ, Константинов БА, Цирульникова ОМ. Трансплантация печени. М.: МИА, 2008: 246.</mixed-citation><mixed-citation xml:lang="en">Gautier SV, Konstantinov BA, Tsirul’nikova OM. Transplantatsiya pecheni. M.: MIA, 2008: 246.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">United Network for Organ Sharing. [Электронный ресурс] – Режим доступа: http://www. unos.org.</mixed-citation><mixed-citation xml:lang="en">United Network for Organ Sharing. [Электронный ресурс] – Режим доступа: http://www. unos.org.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Eurotransplant international foundation. Annual Report [Электронный ресурс] – Режим доступа: www.eurotransplant.nl/files/statistics.</mixed-citation><mixed-citation xml:lang="en">Eurotransplant international foundation. Annual Report [Электронный ресурс] – Режим доступа: www.eurotransplant.nl/files/statistics.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hughes RD, Mitry RR, Dhawan A. Current status of hepatocyte transplantation. Transplantation. 2012; 93: 342–347. doi: 10.1097/TP.0b013e31823b72d6.</mixed-citation><mixed-citation xml:lang="en">Hughes RD, Mitry RR, Dhawan A. Current status of hepatocyte transplantation. Transplantation. 2012; 93: 342–347. doi: 10.1097/TP.0b013e31823b72d6.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Burkhardt B, Martinez-Sanchez JJ, Bachmann A, Ladurner R, Nüssler AK. Long-term culture of primary hepatocytes: new matrices and microfluidic devices. Hepatology International. 2014; 8: 14–22. doi: 10.1007/s12072-013-9487-3/.</mixed-citation><mixed-citation xml:lang="en">Burkhardt B, Martinez-Sanchez JJ, Bachmann A, Ladurner R, Nüssler AK. Long-term culture of primary hepatocytes: new matrices and microfluidic devices. Hepatology International. 2014; 8: 14–22. doi: 10.1007/s12072-013-9487-3/.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta S .Cell therapy to remove excess copper in Wilson’s disease. Annals of the New York Academy of Sciences. 2014; 1315, Issue 1: 70–80. doi: 10.1111/nyas.12450/.</mixed-citation><mixed-citation xml:lang="en">Gupta S .Cell therapy to remove excess copper in Wilson’s disease. Annals of the New York Academy of Sciences. 2014; 1315, Issue 1: 70–80. doi: 10.1111/nyas.12450/.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tanimizu N, Ichinohe N, Ishii M, Kino J, Mizuguchi T, Hirata K, Mitaka T. Liver Progenitors Isolated from Adult Healthy Mouse Liver Efficiently Differentiate to Functional Hepatocytes In Vitro and Repopulate Liver Tissue. Stem Cells. 2016; 34, Issue 12: 2889–2901. doi: 10.1002/stem.2457/.</mixed-citation><mixed-citation xml:lang="en">Tanimizu N, Ichinohe N, Ishii M, Kino J, Mizuguchi T, Hirata K, Mitaka T. Liver Progenitors Isolated from Adult Healthy Mouse Liver Efficiently Differentiate to Functional Hepatocytes In Vitro and Repopulate Liver Tissue. Stem Cells. 2016; 34, Issue 12: 2889–2901. doi: 10.1002/stem.2457/.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yovchev MI, Xue Y, Shafritz DA, Locker J, Oertel M. Repopulation of the fibrotic/cirrhotic rat liver by transplanted hepatic stem/progenitor cells and mature hepatocytes. Hepatology. 2014; 59: 284–295. doi: 10.1002/hep.26615/.</mixed-citation><mixed-citation xml:lang="en">Yovchev MI, Xue Y, Shafritz DA, Locker J, Oertel M. Repopulation of the fibrotic/cirrhotic rat liver by transplanted hepatic stem/progenitor cells and mature hepatocytes. Hepatology. 2014; 59: 284–295. doi: 10.1002/hep.26615/.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Grompe M. Liver stem cells, where art thou? Cell Stem Cell. 2014; 15: 257–258. doi: 10.1016/j.stem.2014.08.004.</mixed-citation><mixed-citation xml:lang="en">Grompe M. Liver stem cells, where art thou? Cell Stem Cell. 2014; 15: 257–258. doi: 10.1016/j.stem.2014.08.004.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ichinohe N, Tanimizu N, Ooe H et al. Differentiation capacity of hepatic stem/pro-genitor cells isolated from Dgalactosamine-treated rat livers. Hepatology. 2013; 57: 1192–1202.</mixed-citation><mixed-citation xml:lang="en">Ichinohe N, Tanimizu N, Ooe H et al. Differentiation capacity of hepatic stem/pro-genitor cells isolated from Dgalactosamine-treated rat livers. Hepatology. 2013; 57: 1192–1202.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mallanna SK, Duncan SA. Differentiationof hepatocytes from pluripotent stem cells. Curr Protoc Stem Cell Biol. 2013; 26: Unit1G 4.</mixed-citation><mixed-citation xml:lang="en">Mallanna SK, Duncan SA. Differentiationof hepatocytes from pluripotent stem cells. Curr Protoc Stem Cell Biol. 2013; 26: Unit1G 4.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Irudayaswamy A, Muthiah M, Zhou L et al. Long-term fate of human fetal liver progenitor cells transplanted in injured mouse livers. Stem Cells. 2018; 36: 103–113.</mixed-citation><mixed-citation xml:lang="en">Irudayaswamy A, Muthiah M, Zhou L et al. Long-term fate of human fetal liver progenitor cells transplanted in injured mouse livers. Stem Cells. 2018; 36: 103–113.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Soeder Y, Loss M, Johnson CL, Hutchinson JA, Haarer J, Ahrens N et al. First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation. Stem Cells Transl Med. 2015; 4 (8): 899–904. doi: 10.5966/sctm.2015-0002.</mixed-citation><mixed-citation xml:lang="en">Soeder Y, Loss M, Johnson CL, Hutchinson JA, Haarer J, Ahrens N et al. First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation. Stem Cells Transl Med. 2015; 4 (8): 899–904. doi: 10.5966/sctm.2015-0002.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Dillmann J, Popp FC, Fillenberg B, Zeman F, Eggenhofer E, Farkas S et al. Treatment-emergent adverse events after infusion of adherent stem cells: the MiSOT-I score for solid organ transplantation. Trials. 2012; 15 (13): 211–221. doi: 10.1186/1745-6215-13-211.</mixed-citation><mixed-citation xml:lang="en">Dillmann J, Popp FC, Fillenberg B, Zeman F, Eggenhofer E, Farkas S et al. Treatment-emergent adverse events after infusion of adherent stem cells: the MiSOT-I score for solid organ transplantation. Trials. 2012; 15 (13): 211–221. doi: 10.1186/1745-6215-13-211.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Popp FC, Fillenberg B, Eggenhofer E, Renner P, Dillmann J, Benseler V et al. Safety and feasibility of thirdparty multipotent adult progenitor cells for immunomodulation therapy after liver transplantation – a phase I study (MISOT-I). J Transl Med. 2011; 28 (9): 124. doi: 10.1186/1479-5876-9-124.</mixed-citation><mixed-citation xml:lang="en">Popp FC, Fillenberg B, Eggenhofer E, Renner P, Dillmann J, Benseler V et al. Safety and feasibility of thirdparty multipotent adult progenitor cells for immunomodulation therapy after liver transplantation – a phase I study (MISOT-I). J Transl Med. 2011; 28 (9): 124. doi: 10.1186/1479-5876-9-124.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chistiakov DA. Liver regenerative medicine: advances and challenges. Cells Tissues Organs. 2012; 4 (196): 291–312.</mixed-citation><mixed-citation xml:lang="en">Chistiakov DA. Liver regenerative medicine: advances and challenges. Cells Tissues Organs. 2012; 4 (196): 291–312.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lee SY, Kim HJ, Choi D. Cell Sources, Liver Support Systems and Liver Tissue Engineering: Alternatives to Liver Transplantation. International Journal of Stem Cells. 2015; 8 (1): 36–47. doi: 10.15283/ijsc.2015.8.1.36.</mixed-citation><mixed-citation xml:lang="en">Lee SY, Kim HJ, Choi D. Cell Sources, Liver Support Systems and Liver Tissue Engineering: Alternatives to Liver Transplantation. International Journal of Stem Cells. 2015; 8 (1): 36–47. doi: 10.15283/ijsc.2015.8.1.36.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Matsuzawa A, Matsusaki M, Akashi M. Construction of three-dimensional liver tissue models by cell accumulation technique and maintaining their metabolic functions for long-term culture without medium change. J Biomed Mater Res A. 2015 Apr; 103 (4): 1554–1564. doi: 10.1002/jbm.a.35292. Epub 2014 Aug 12.</mixed-citation><mixed-citation xml:lang="en">Matsuzawa A, Matsusaki M, Akashi M. Construction of three-dimensional liver tissue models by cell accumulation technique and maintaining their metabolic functions for long-term culture without medium change. J Biomed Mater Res A. 2015 Apr; 103 (4): 1554–1564. doi: 10.1002/jbm.a.35292. Epub 2014 Aug 12.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Sakai Y, Yamanouchi K, Ohashi K. Vascularized subcutaneous human liver tissue from engineered hepatocyte/ fibroblast sheets in mice. Biomaterials. 2015; 65: 66–75. doi: 10.1016/j.biomaterials.2015.06.046.</mixed-citation><mixed-citation xml:lang="en">Sakai Y, Yamanouchi K, Ohashi K. Vascularized subcutaneous human liver tissue from engineered hepatocyte/ fibroblast sheets in mice. Biomaterials. 2015; 65: 66–75. doi: 10.1016/j.biomaterials.2015.06.046.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Fujii M, Yamanouchi K, Sakai Y, Baimakhanov Z, Yamaguchi I, Soyama A et al. In vivoconstruction of liver tissue by implantation of ahepatic non-parenchymal/ adipose-derived stem cellsheet. J Tissue Eng Regen Med. 2017; 21. doi: 10.1002/term.2424.</mixed-citation><mixed-citation xml:lang="en">Fujii M, Yamanouchi K, Sakai Y, Baimakhanov Z, Yamaguchi I, Soyama A et al. In vivoconstruction of liver tissue by implantation of ahepatic non-parenchymal/ adipose-derived stem cellsheet. J Tissue Eng Regen Med. 2017; 21. doi: 10.1002/term.2424.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Shu Q Liu. Bioregenerative Engineering: Principles and Applications. Wiley-interscience A. John Willey &amp; Sons, inc., Hoboken, New Jersey Publication. 2007. 1053 p.</mixed-citation><mixed-citation xml:lang="en">Shu Q Liu. Bioregenerative Engineering: Principles and Applications. Wiley-interscience A. John Willey &amp; Sons, inc., Hoboken, New Jersey Publication. 2007. 1053 p.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Zhao X, Liang L, Wang S. A decade of progress in liver regenerative medicine Review article. Biomaterials. 2018; 157: 161–176. doi: 10.1016/j.biomaterials.2017.11.027.</mixed-citation><mixed-citation xml:lang="en">Zhang J, Zhao X, Liang L, Wang S. A decade of progress in liver regenerative medicine Review article. Biomaterials. 2018; 157: 161–176. doi: 10.1016/j.biomaterials.2017.11.027.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Sasaki K, Akagi T, Asaoka T, Eguchi H, Akashi M. Construction of three-dimensional vascularized functional human liver tissue using a layer-by-layer cell coating technique. Biomaterials. 2017; 133: 263–274.</mixed-citation><mixed-citation xml:lang="en">Sasaki K, Akagi T, Asaoka T, Eguchi H, Akashi M. Construction of three-dimensional vascularized functional human liver tissue using a layer-by-layer cell coating technique. Biomaterials. 2017; 133: 263–274.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Nicolas C, Hickey R, Chen H, Mao S, Higuita M, Wang Y, Nyberg S. Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengineered Grafts. Stem Cells. 2017; 35 (1): 42–50.</mixed-citation><mixed-citation xml:lang="en">Nicolas C, Hickey R, Chen H, Mao S, Higuita M, Wang Y, Nyberg S. Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengineered Grafts. Stem Cells. 2017; 35 (1): 42–50.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ishak K et al. Гистологическая оценка стадии и степени хронического гепатита. Клиническая гепатология. 2010; 2: 8–11.</mixed-citation><mixed-citation xml:lang="en">Ishak K et al. Gistologicheskaya otsenka stadii i stepeni khronicheskogo gepatita. Klinicheskaya gepatologiya. 2010; 2: 8–11.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Автандилов ГГ. Медицинская морфометрия: руководство. М.: Медицина, 1990. 384.</mixed-citation><mixed-citation xml:lang="en">Avtandilov GG. Meditsinskaya morfometriya: rukovodstvo. M.: Meditsina, 1990. 384.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
